RxDoctor Payments Data

Stephanie Buck-Haskin, MD

Obstetrics & Gynecology · Great Neck, NYNPI 1952362774

Payments from drug & device makers

$25,273in general payments, 2019–2025

Across 437 payments — averaging $57.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lupin Inc.$11K
  • Pfizer$4K
  • AbbVie$3K
  • Astellas Pharma US Inc$861
  • Agile Therapeutics, Inc.$733
  • Myovant Sciences Inc.$679
  • plus $6K from 29 others

What the payments were for

  • Consulting fees$6002%
  • Speaking & faculty fees$12,81551%
  • Food & beverage$11,24044%
  • Education$6192%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,273 in reported general payments places this provider in the 95th percentile of 2,673 obstetrics & gynecology providers in New York.

See all obstetrics & gynecology providers in New York

Medicare billing

Part B allowed, 2024
$73,918
Medicare patients
100
Services billed
528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IntrarosaPrasterone (Dhea)36$11,401
MyrbetriqMirabegron15$7,518
Estradiol101$5,122
PremarinEstrogens, Conjugated11$4,581
Clobetasol Propionate42$2,523
Clindamycin Phosphate41$1,574
Metronidazole90$1,441
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip63$1,136
ValacyclovirValacyclovir Hcl18$555
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst39$364
Nystatin20$308
Fluconazole74$297
Doxycycline Hyclate31$119
Ciprofloxacin Hcl15$60
Naproxen11$47

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AMAG Pharmaceuticals, Inc.Intrarosa$319$11,40136 claims
Astellas Pharma US IncMyrbetriq$861$7,51815 claims
PfizerPremarin$4,092$4,58111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,673 obstetrics & gynecology providers in New York.

Other obstetrics & gynecology in Great Neck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →